SAVA Stock Price, Cassava Sciences Inc Quote, Chart

Market Summary

USD23.13+1.57

Delayed

7.28%

SAVA Stock Price

View Fullscreen

SAVA RSI Chart

SAVA Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-23.17

Price/Sales (Trailing)

364.7

EV/EBITDA

-72.99

Price/Free Cashflow

-12.62

SAVA Price/Sales (Trailing)

SAVA Profitability

EBT Margin

-509.36%

Return on Equity

-60.95%

Return on Assets

-30.76%

Free Cashflow Yield

-7.93%

SAVA Fundamentals

SAVA Revenue

Revenue (TTM)

2.8M

SAVA Earnings

Earnings (TTM)

-47.9M

Earnings Growth (Yr)

203.18%

Earnings Growth (Qtr)

219.71%

Breaking Down SAVA Revenue

Last 7 days

14.3%

Last 30 days

8.7%

Last 90 days

-2.6%

Trailing 12 Months

-6.1%

How does SAVA drawdown profile look like?

SAVA Financial Health

Current Ratio

1.74

SAVA Investor Care

Shares Dilution (1Y)

14.91%

Diluted EPS (TTM)

-2.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	73.0K	374.0K	1.2M	2.8M
2021	47.0K	33.0K	41.0K	49.0K
2020	308.0K	241.0K	166.0K	112.0K
2019	190.5K	275.5K	340.5K	328.0K
2018	24.0K	27.0K	38.0K	105.5K
2017	94.0K	71.0K	54.0K	38.0K
2016	79.0K	95.0K	103.0K	107.0K
2015	45.0K	47.0K	51.0K	57.0K
2014	30.9M	20.6M	10.3M	47.0K
2013	9.9M	9.1M	8.3M	41.1M
2012	11.2M	11.2M	11.2M	10.9M
2011	16.8M	16.9M	16.7M	11.5M
2010	0	19.3M	18.1M	16.8M
2009	0	0	0	20.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cassava Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 26, 2024	robertson sanford	acquired	1,518,000	22.00	69,000	-
Apr 23, 2024	barry richard	acquired	3,873,870	22.00	176,085	-
Apr 18, 2024	kupiec james william	acquired	33,000	22.00	1,500	chief medical officer
Apr 17, 2024	schoen eric	acquired	33,000	22.00	1,500	chief financial officer
Aug 23, 2023	robertson sanford	bought	523,500	17.45	30,000	-
Aug 22, 2023	barry richard	bought	275,907	16.65	16,571	-
Aug 21, 2023	barry richard	bought	32,020	16.8	1,906	-
Jun 12, 2023	scannon patrick j md phd	acquired	950	0.95	1,000	-
May 24, 2023	barbier remi	sold (taxes)	-241,011	25.25	-9,545	president and ceo
May 24, 2023	barbier remi	sold (taxes)	-1,205,010	25.25	-47,723	president and ceo

Which funds bought or sold SAVA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Ancora Advisors LLC	new	-	806	806	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.58	-132,445	814,258	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	132,060	132,060	-%
May 16, 2024	COMERICA BANK	unchanged	-	-444	4,058	-%
May 16, 2024	Ancora Advisors LLC	unchanged	-	-1,110	10,145	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-74.24	-6,467,680	1,955,690	-%
May 15, 2024	Royal Bank of Canada	new	-	3,000	3,000	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	149,944	149,944	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	573	573	-%
May 15, 2024	Cable Car Capital LLC	new	-	402,990	402,990	0.56%

Are Funds Buying or Selling SAVA?

Are funds buying SAVA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SAVA

No. of Funds

Unveiling Cassava Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.51%	2,324,626	SC 13G/A
Feb 01, 2024	barbier remi	5.7%	2,488,531	SC 13G/A
Jan 26, 2024	blackrock inc.	7.2%	3,037,415	SC 13G/A
Feb 09, 2023	vanguard group inc	5.27%	2,196,925	SC 13G/A
Feb 08, 2023	cassava sciences inc	-	2	SC 13G/A
Feb 01, 2023	blackrock inc.	6.1%	2,564,528	SC 13G/A
Feb 09, 2022	vanguard group inc	5.15%	2,060,819	SC 13G
Feb 03, 2022	barbier remi	5.%	20	SC 13G/A
Feb 03, 2022	blackrock inc.	6.9%	2,760,978	SC 13G/A
Feb 16, 2021	cvi investments, inc.	0%	0	SC 13G/A

Recent SEC filings of Cassava Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	8-K	Current Report

Peers (Alternatives to Cassava Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cassava Sciences Inc News

Latest updates

Cassava Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	77.0%	1,554,000	878,000	314,000	31,000	14,000	15,000	13,000	7,000	6,000	7,000	27,000	72,000	60,000	82,000	94,000	92,000	72,500	17,000	9,000	7,000	5,000
Operating Expenses	-1.9%	20,937,000	21,345,000	19,917,000	17,821,000	14,444,000	9,753,000	5,138,000	3,533,000	2,624,000	1,437,000	1,163,000	1,222,000	1,576,000	779,000	1,153,000	1,451,000	750,000	1,284,000	2,461,000	-	-
S&GA Expenses	16.5%	3,285,000	2,819,000	2,969,000	2,915,000	4,102,000	1,712,000	1,237,000	1,004,000	1,105,000	1,038,000	818,000	778,000	838,000	831,000	845,000	877,000	748,000	848,000	998,000	1,099,000	-
R&D Expenses	-4.7%	17,652,000	18,526,000	-	-	-	-	-	-	-	-	-	-	-	-	308,000	574,000	-511,500	1,463,000	1,463,000	1,068,000	1,544,500
EBITDA Margin	55.8%	-4.49	-10.14	-33.71	-174	-264	-320	-401	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	55.5%	-5.09	-11.43	-37.82	-193	-288	-345	-428	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	5.5%	-19,134,000	-20,257,000	-19,328,000	-17,527,000	-14,172,000	-9,562,000	-5,125,000	-3,526,000	-2,618,000	-1,430,000	-1,136,000	-1,150,000	-1,516,000	-697,000	-1,059,000	-1,359,000	-677,500	-1,267,000	-2,452,000	-	-
Net Income Margin	52.4%	-27.46	-57.63	-162	-635	-660	-508	-384	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	7.6%	-20,985,000	-22,706,000	-12,580,000	-23,955,000	-8,087,000	-36,805,000	-5,139,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.7%	156	152	173	197	218	235	207	227	244	267	274	281	284	94.00	25.00	25.00	26.00	23.00	18.00	19.00	20.00
Current Assets	3.4%	134	130	150	175	195	211	183	204	222	244	252	280	284	94.00	25.00	25.00	26.00	23.00	18.00	19.00	19.00
Cash Equivalents	2.5%	124	121	142	168	187	201	175	197	210	233	242	278	282	94.00	24.00	25.00	26.00	23.00	18.00	19.00	19.00
Net PPE	-1.1%	22.00	22.00	22.00	22.00	23.00	23.00	23.00	22.00	21.00	21.00	21.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-100.0%	-	14.00	17.00	18.00	14.00	7.00	9.00	9.00	7.00	13.00	7.00	5.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Current Liabilities	443.3%	77.00	14.00	17.00	18.00	14.00	7.00	8.00	9.00	7.00	13.00	6.00	5.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Shareholder's Equity	-42.8%	79.00	137	155	179	204	228	199	218	237	254	268	276	281	92.00	24.00	24.00	25.00	22.00	17.00	18.00	19.00
Retained Earnings	6.6%	-355	-380	-359	-334	-307	-283	-264	-244	-224	-207	-193	-183	-178	-174	-172	-170	-169	-168	-167	-166	-165
Additional Paid-In Capital	-16.2%	434	518	515	514	512	511	463	462	462	461	461	460	460	267	196	195	195	191	184	184	184
Shares Outstanding	2.4%	43.00	42.00	42.00	42.00	42.00	42.00	40.00	40.00	40.00	39.00	40.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	967	-	-	-	1,100	-	-	-	3,200	-	-	-	71.00	-	-	-	19.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	14.3%	-19,127	-22,316	-26,530	-19,924	-13,255	-21,320	-21,550	-11,114	-23,530	-7,987	-14,764	-5,139	-2,306	-1,175	-2,171	-842	-1,194	-589	-730	-591	-604
Share Based Compensation	9.7%	2,335	2,129	949	835	673	616	470	485	495	1,001	24.00	5.00	250	482	4.00	249	9.00	465	1.00	328	342
Cashflow From Investing	100.0%	-	-41.00	-22.00	6.00	-357	335	-1,156	-1,466	-425	-100	-22,041	-	-	-	-	260	100	-	-	-	-18.00
Cashflow From Financing	1838.8%	22,160	1,143	464	889	64.00	47,338	136	119	211	-	75.00	1,274	190,992	70,607	991	236	3,613	5,866	-	-	-60.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SAVA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 16,233	$ 22,120
General and administrative	3,701	4,392
Total operating expenses	19,934	26,512
Operating loss	(19,934)	(26,512)
Interest income	1,776	2,051
Other income, net	160	190
Gain from change in fair value of warrant liabilities	43,041	0
Net income (loss)	$ 25,043	$ (24,271)
Shares used in computing net income (loss) per share, basic (in shares)	43,001	41,739
Net income (loss) per share, basic (in dollars per share)	$ 0.58	$ (0.58)
Net income (loss)	$ 25,043	$ (24,271)
Adjustment for change in fair value of warrant liabilities	(43,792)	0
Adjusted numerator, diluted	$ (18,749)	$ (24,271)
Shares used in computing net loss per share, diluted (in shares)	44,102	41,739
Net loss per share, diluted (in dollars per share)	$ (0.43)	$ (0.58)

SAVA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 124,169	$ 121,136
Prepaid expenses and other current assets	9,830	8,497
Total current assets	133,999	129,633
Property and equipment, net	21,604	21,854
Intangible assets, net	115	176
Total assets	155,718	151,663
Current liabilities:
Accounts payable and accrued expenses	9,603	10,573
Accrued development expense	1,797	3,037
Accrued compensation and benefits	228	200
Warrant liabilities	65,368	0
Other current liabilities	125	385
Total current liabilities	77,121	14,195
Commitments and contingencies (Notes 9, 10 and 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized; 43,248,416 and 42,236,919 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	43	42
Additional paid-in capital	434,280	518,195
Retained Earnings (Accumulated Deficit)	(355,726)	(380,769)
Total stockholders' equity	78,597	137,468
Total liabilities and stockholders' equity	$ 155,718	$ 151,663

About Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

CEO	Mr. Remi Barbier
WEBSITE	cassavasciences.com
INDUSTRY	Biotechnology
EMPLOYEES	26

Cassava Sciences Inc Frequently Asked Questions

What is the ticker symbol for Cassava Sciences Inc? What does SAVA stand for in stocks?

SAVA is the stock ticker symbol of Cassava Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cassava Sciences Inc (SAVA)?

As of Fri May 17 2024, market cap of Cassava Sciences Inc is 1.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SAVA stock?

You can check SAVA's fair value in chart for subscribers.

What is the fair value of SAVA stock?

You can check SAVA's fair value in chart for subscribers. The fair value of Cassava Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cassava Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SAVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cassava Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether SAVA is over valued or under valued. Whether Cassava Sciences Inc is cheap or expensive depends on the assumptions which impact Cassava Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SAVA.

What is Cassava Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SAVA's PE ratio (Price to Earnings) is -23.17 and Price to Sales (PS) ratio is 364.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SAVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cassava Sciences Inc's stock?

In the past 10 years, Cassava Sciences Inc has provided -0.033 (multiply by 100 for percentage) rate of return.